Latest Interviews

Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity

Andrew Huberman, Daisy Wolf

Professor Andrew Huberman outlined a major shift in consumer health toward proactive management driven by the pandemic, highlighting the transformative impact of GLP-1 drugs and non-GLP peptides on obesity treatment and tissue repair. The discussion detailed critical nutritional and circadian interventions, such as strategic carbohydrate timing and core-body cooling, alongside emerging AI diagnostics and "write-to-biology" technologies aimed at extending human lifespan toward one hundred years. Huberman further emphasized the need for scientific literacy amidst political polarization while predicting rapid adoption of sleep optimization devices and real-time biomarker monitoring within the next five years.